Baillie Gifford & CO Aslan Pharmaceuticals LTD Transaction History

Baillie Gifford & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 10, 2020	SELL	$0.37 - $5.2 $154,908 - $2.18 Million	-418,671 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$1.51 - $3.85 $15,559 - $39,670	-10,304 Reduced 2.4%	418,671 $724,000
Q2 2019 Aug 08, 2019	SELL	$2.91 - $4.5 $38,467 - $59,485	-13,219 Reduced 2.99%	428,975 $1.32 Million
Q1 2019 May 01, 2019	SELL	$3.1 - $4.8 $24,610 - $38,107	-7,939 Reduced 1.76%	442,194 $0
Q2 2018 Jul 17, 2018	BUY	$5.48 - $10.24 $2.47 Million - $4.61 Million	450,133 New	450,133 $3.96 Million

Ticker ASLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,744,704
Market Cap $41.8M
Description
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-m...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.